These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 23252795)

  • 1. Adverse events associated with mTOR inhibitors.
    Pallet N; Legendre C
    Expert Opin Drug Saf; 2013 Mar; 12(2):177-86. PubMed ID: 23252795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current and future directions in mammalian target of rapamycin inhibitors development.
    Fasolo A; Sessa C
    Expert Opin Investig Drugs; 2011 Mar; 20(3):381-94. PubMed ID: 21299441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
    Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
    Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus.
    Sánchez-Fructuoso AI; Ruiz JC; Pérez-Flores I; Gómez Alamillo C; Calvo Romero N; Arias M
    Transplant Proc; 2010 Oct; 42(8):3050-2. PubMed ID: 20970607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation.
    Somers MJ; Paul E
    J Clin Pharmacol; 2015 Apr; 55(4):368-76. PubMed ID: 25402866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Furthering the design and the discovery of small molecule ATP-competitive mTOR inhibitors as an effective cancer treatment.
    Lv X; Ma X; Hu Y
    Expert Opin Drug Discov; 2013 Aug; 8(8):991-1012. PubMed ID: 23668243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. mTOR kinase inhibitors as a treatment strategy in hematological malignancies.
    Grzybowska-Izydorczyk O; Smolewski P
    Future Med Chem; 2012 Mar; 4(4):487-504. PubMed ID: 22416776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Everolimus for the treatment of advanced renal cell carcinoma.
    Amato R
    Expert Opin Pharmacother; 2011 May; 12(7):1143-55. PubMed ID: 21470068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis.
    Xu J; Tian D
    Curr Med Res Opin; 2014 Jan; 30(1):67-74. PubMed ID: 24028709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temsirolimus: a safety and efficacy review.
    Bukowski RM
    Expert Opin Drug Saf; 2012 Sep; 11(5):861-79. PubMed ID: 22861825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in the discovery of small-molecule ATP competitive mTOR inhibitors: a patent review.
    Zask A; Verheijen JC; Richard DJ
    Expert Opin Ther Pat; 2011 Jul; 21(7):1109-27. PubMed ID: 21591993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting mTOR in mantle cell lymphoma: current and future directions.
    Smith SM
    Best Pract Res Clin Haematol; 2012 Jun; 25(2):175-83. PubMed ID: 22687453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications.
    Danesi R; Boni JP; Ravaud A
    Cancer Treat Rev; 2013 Nov; 39(7):784-92. PubMed ID: 23375248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. mTOR in renal cell cancer: modulator of tumor biology and therapeutic target.
    Wysocki PJ
    Expert Rev Mol Diagn; 2009 Apr; 9(3):231-41. PubMed ID: 19379082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and risk of treatment-related mortality in cancer patients treated with the mammalian target of rapamycin inhibitors.
    Choueiri TK; Je Y; Sonpavde G; Richards CJ; Galsky MD; Nguyen PL; Schutz F; Heng DY; Kaymakcalan MD
    Ann Oncol; 2013 Aug; 24(8):2092-7. PubMed ID: 23658373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions.
    Fernandes-Silva G; Ivani de Paula M; Rangel ÉB
    Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):367-385. PubMed ID: 27659512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies.
    Khokhar NZ; Altman JK; Platanias LC
    Curr Opin Oncol; 2011 Nov; 23(6):578-86. PubMed ID: 21892085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current phase II clinical data for ridaforolimus in cancer.
    Spreafico A; Mackay HJ
    Expert Opin Investig Drugs; 2013 Nov; 22(11):1485-93. PubMed ID: 23964772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy of sclerodermatous chronic graft-versus-host disease with mammalian target of rapamycin inhibitors.
    Jedlickova Z; Burlakova I; Bug G; Baurmann H; Schwerdtfeger R; Schleuning M
    Biol Blood Marrow Transplant; 2011 May; 17(5):657-63. PubMed ID: 20696263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer.
    Diaz-Padilla I; Duran I; Clarke BA; Oza AM
    Cancer Treat Rev; 2012 Oct; 38(6):767-75. PubMed ID: 22381585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.